Loading
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Latest quote
$14.56
+$0.31 · +2.18%
After-hours
$14.56
$0.00 · 0.00%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Day range
Current $14.56
52-week range
Current $14.56
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
65
Bullish
Risk
36
Moderate Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Day range
Current $14.56
52-week range
Current $14.56
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 97K USD | — | — | — | — |
| Gross profit | −97K USD | — | — | — | — |
| Research and development | 46.62M USD | 14.34M USD | 15.41M USD | 26.21M USD | 23.32M USD |
| Selling, general, and administrative | 21.17M USD | 16.03M USD | 24.86M USD | 18.92M USD | 12.35M USD |
| Operating expenses | 67.79M USD | 82.02M USD | 40.28M USD | 45.14M USD | 35.67M USD |
| Interest income | 8.32M USD | 8.13M USD | 4.62M USD | 1.38M USD | — |
| Depreciation and amortization | 97K USD | — | — | — | — |
| Operating income | −67.88M USD | −82.02M USD | −40.28M USD | −45.14M USD | −35.67M USD |
| Net income | −59.85M USD | −73.9M USD | −35.12M USD | −45.24M USD | −47.48M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$26.55
82.35% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.26M0.00%2.3T USD0.03%$374.68-0.43%
iShares Russell 2000 ETFIWM13.34M0.02%78.38B USD0.19%$287.91-0.34%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS5.34M1.28%415.99M USD0.60%$108.11-1.70%
Vanguard Extended Market ETFVXF3.48M0.00%93.7B USD0.05%$236.92-0.35%
Vanguard Russell 2000 ETFVTWO2.35M0.01%17.4B USD0.06%$116.37-0.33%
iShares Russell 2000 Growth ETFIWO2.07M0.01%14.39B USD0.24%$365.6-0.55%
iShares Micro-Cap ETFIWC1.71M0.12%1.44B USD0.60%$190.92+0.04%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.59M0.11%1.59B USD0.43%$35.16-1.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Dorsey Wright SmallCap Momentum ETFDWASVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCFidelity Fundamental Small-Mid Cap ETFFFSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
